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Cutaneous Endothelial Cell Activation in Normal Skin
of Patients with Dermatitis Herpetiformis Associated
with Increased Serum Levels of IL-8, sE-Selectin, and
TNF-a
Russell P. Hall III1, Fumiko Takeuchi1, Keith M. Benbenisty1 and Robert D. Streilein1
The mechanisms that lead to the development of skin lesions in patients with dermatitis herpetiformis (DH) are
not known. We hypothesized that an ongoing immune response in the gut of patients with DH would result in
an increase in circulating cytokines and be associated with endothelial cell activation, creating a
proinflammatory environment in the skin. Skin biopsies from the normal-appearing inner arm of 11 DH
patients, with no active skin lesions, and 12 normal subjects were analyzed for E-selectin (E-sel) and ICAM-1
mRNA. DH patients’ skin expressed markedly increased levels of E-sel mRNA. Mean E-sel mRNA expression in
DH skin was 1,271 (range 63.78–5861) times greater than that of a control, normal skin (Po0.001) with no
significant increased expression of ICAM-1 mRNA. Serum levels of soluble E-selectin (sE-sel), IgA anti-tissue
transglutaminase antibodies, and serum IL-8 levels were significantly increased in patients with DH. These
studies demonstrate that patients with DH have evidence of endothelial cell activation in the skin and systemic
manifestations of the ongoing inflammation associated with the mucosal immune response. Endothelial cell
activation may play a critical role in the development of skin lesions in patients with DH and may represent a
common mechanism for cutaneous manifestations of inflammatory gastrointestinal diseases.
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INTRODUCTION
Dermatitis herpetiformis (DH) is characterized by extremely
pruritic papules and vesicles that preferentially develop over
the elbows, knees, and other extensor surfaces (Hall, 1992;
Fry, 1995). These lesions have a distinctive inflammatory
infiltrate consisting of an accumulation of neutrophils at the
dermal–epidermal junction, often localizing to the papillary
tips of the basement membrane zone. This infiltrate is almost
entirely made up of neutrophils and is not typically
associated with any destruction of the dermal vasculature
or significant perivascular accumulation of neutrophils. The
factors that are important in the development of the skin
lesions of DH are not known, although the ability to control
this inflammation by the strict adherence to a gluten-free diet
(GFD) suggests that the mucosal immune response plays a
critical role in the pathogenesis of the skin lesions (Reunala,
1978; Fry et al., 1982).
The movement of neutrophils through blood vessel walls
and their localization in the tissue is a complex process. Entry
of neutrophils into tissue is controlled by a cascade of
multiple molecular interactions that can be divided into three
stages: (1) tethering and rolling of neutrophils on the
endothelium, (2) activation of integrins, and (3) firm adhesion
and extravasation of neutrophils into the skin (Bevilacqua and
Nelson, 1993; Springer, 1994; Witko-Sarsat et al., 2000;
Muller, 2002). We have previously demonstrated that
circulating neutrophils in patients with DH show signs of
activation with increased expression of CD11b and de-
creased expression of neutrophil L-selectin (Smith et al.,
2002). For neutrophils to become actively involved in an
inflammatory process, however, they must be tethered and
roll on the endothelium before they can firmly adhere and
extravasate into tissue. The ability to actively tether inflam-
matory cells to the endothelium, however, requires participa-
tion of adhesion proteins such as E-selectin (E-sel) that are not
expressed to a large extent on resting endothelial cell surfaces
(Cotran et al., 1986; Lawrence and Springer, 1993).
Previous studies have demonstrated that systemic inflam-
mation can result in the activation of endothelial cells with
increased expression of soluble E-selectin (sE-sel) in the sera.
Increased sE-sel has been found in the sera of patients with
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a wide range of inflammatory diseases including rheumatoid
arthritis, inflammatory bowel disease, and bacterial endo-
carditis (Soderquist et al., 1999; Kuuliala et al., 2002; Leone
et al., 2002; Magro et al., 2004; Sari et al., 2005). Jelinkova
et al. (2000) have reported elevated levels of sE-sel in the sera
of patients with isolated gluten-sensitive enteropathy, both
on gluten-free and gluten-containing diets. These reports,
however, have not examined specific organs for increased
expression of E-sel. It is not clear if the increase in sE-sel is
secondary to target organ inflammation alone or a general-
ized endothelial cell response occurs with increased expres-
sion of endothelial cell E-sel in other organs such as the skin.
We hypothesized that the presence of an ongoing mucosal
immune response in the gut of patients with DH may result
in increased levels of proinflammatory cytokines in the sera,
which could result in an increased expression of adhesion
proteins on endothelial cells of the skin, facilitating the
development of inflammatory infiltrates in the skin of patients
with DH. We have found an increased expression of E-sel
mRNA in the normal-appearing skin of patients with DH
associated with increased serum levels of sE-sel, IgA anti-
tissue transglutaminase (TTG), serum IL-8, and serum tumor
necrosis factor-a (TNF-a). These results suggests that the
presence of an active mucosal inflammatory response in the
gut of patients with DH is associated with an activation of
cutaneous endothelial cells as well as circulating inflamma-
tory cells and that these processes may play a key role in
the development of the skin lesions of DH. These findings
also may provide a pathogenic mechanism important in
the development of the skin lesions associated with a variety
of gastrointestinal inflammatory diseases.
RESULTS
Increased expression of E-sel mRNA in normal inner arm skin of
patients with DH with no increase in the expression of ICAM-1
mRNA
Expression of E-sel mRNA was elevated in the normal-
appearing inner arm skin of 10 of 10 patients with DH
ranging from 63.8 to 5,861 times the designated normal value
(mean¼ 1,271 times normal) (Figure 1). In one DH patient,
E-sel expression at the inner arm site was not measured owing
to technical difficulties. E-sel expression in the elbow skin of
that patient was elevated (622.2 times normal), but is not
included in the figure owing to the different body site.
In contrast, normal subjects showed E-sel mRNA expression
of 1.00–32.6 (mean¼ 8.9) times the value of the designated
normal subject (Figure 1). This difference was statisti-
cally significant using the one-tailed Mann–Whitney U-test
(Po0.0001).
Expression of ICAM-1 mRNA in the skin of patients with
DH was increased in patients with DH compared to normal
subjects; however, this did not reach the level of statistical
significance. ICAM-1 mRNA expression ranged from 0.54
to 33 (mean¼11.6) times the designated normal value in
patients with DH, compared to a range of ICAM-1 mRNA
expression in normal subjects of 0.4–8.3 times the designated
normal value (P¼ 0.2351, Mann–Whitney U-test) (Figure 1).
None of the patients studied had active skin lesions at
the time of study at any body site. Both patients studied on
a GFD for greater than 4 years had increased expression of
E-sel mRNA. In addition, hemoglobin and hematocrit were
within normal limits in eight of nine patients on dapsone or
sulfapyridine, whereas the remaining patient had hemoglobin
of 10.8 gm/dl owing to B12 and iron deficiency.
E-sel protein is present in the normal-appearing skin of patients
with DH
Immunohistochemistry of the skin of all patients with DH
revealed strong expression of ICAM-1 in dermal blood vessels
(Figure 2b). E-sel expression was present in scattered blood
vessels of the upper dermis with both less intensity and
frequency than ICAM-1 in five of six DH patients (Figure 2a).
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Figure 1. Expression of E-sel mRNA is increased in normal-appearing skin of
patients with DH compared to normal subjects. mRNA expression represents
fold expression of a subject compared to a constant single normal subject
value. Expression of E-sel mRNA in the skin of patients with DH is
significantly increased compared to that seen in normal subjects (Po0.0001,
Mann–Whitney U-test). No significant difference is seen in ICAM-1 mRNA
expression.
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Figure 2. Expression of E-sel in blood vessels of normal skin of patients with
DH. Expression of E-sel is seen in blood vessel of (a) normal inner arm skin of
DH patient but not in (c) normal inner arm skin of normal subject. ICAM-1
expression is seen in dermal blood vessels of skin of both (b) patient with
DH and (d) normal subject. Scale bar¼ 50mm.
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No significant expression of E-sel was seen in normal subjects
inner arm skin (Figure 2c). ICAM-1 was strongly expressed
in dermal blood vessels of all normal subjects (Figure 2d).
Neither IgA nor C3 was present around dermal vessels in
the skin of patients with DH, although IgA was present in a
granular pattern at the dermal–epidermal junction consistent
with the diagnosis of DH (data not shown).
Serum IgA anti-TTG antibody, IL-8, TNF-a, sE-sel, and soluble
L-selectin levels in patients with DH
IgA anti-TTG antibodies were present in 28 of 49 (57%)
patients with DH (mean¼63.0 U/ml, range: 2.0–793 U/ml,
normal serao10 U/ml). sE-sel was elevated in 17 of 50 (34%)
of patients compared to one of 11 normal subjects (DH patients,
n¼50, mean¼55.7 ng/ml, range: 0.67174.8 ng/ml; normal
subjects, n¼10, mean¼30.48 ng/ml, range: 1.7–73.34 ng/ml;
manufacturer normal mean¼46.3 ng/ml; range: 29.1–63.4 ng/
ml) (DH patients vs. normal subjects, P¼ 0.0250, Mann–
Whitney U-test) (Figure 3). No significant correlation was seen
between sE-sel and IgA anti-TTG (P40.05, Spearman’s corre-
lation). Soluble L-selectin was elevated in 15 of 50 (30%)
subjects (DH patients, n¼50, mean¼1,121.4 ng/ml, range:
458–1,983 ng/ml; manufacturer normal mean¼954 ng/ml,
71 SD, range: 660–1,250 ng/ml).
Serum IL-8 levels were elevated in 20 of 50 (40%) of
patients with DH. IL-8 values ranged from 1.5 to 5,900 pg/ml
(mean¼ 804.45 pg/ml) (manufacturer normal p31.2 pg/ml)
(Figure 4). This increase was statistically significant when
compared to normal subjects (mean¼ 9.96 pg/ml. range:
4.81–19.443 pg/ml. P¼0.024, Mann–Whitney U-test, one-
tailed test) and to serum IL-8 levels in patients with other
immune mediated skin disease (mean¼ 9.08 pg/ml. range:
1.65–27.95 pg/ml. n¼ 10) (P¼0.029, Mann–Whitney test,
two-tailed test) (Figure 4). There was a positive correlation
between serum IL-8 and serum IgA anti-TTG (r¼0.32,
P¼0.0273, Spearman’s correlation), but not between sE-sel
and serum IL-8 levels (P40.05). Serum TNF-a levels were
elevated above the upper limit of normal in eight of 50 sub-
jects as compared to zero of 11 normal subjects (DH patients,
n¼50, mean¼7.3 pg/ml, range: 0.4–58 pg/ml; normal sub-
jects, n¼ 10, mean¼1.43 pg/ml, range: 0.24–2.98 pg/ml;
manufacturer reported normal mean¼2.07 pg/ml, range:
not detected–4.71 pg/ml) (Figure 5). There was a significant
difference between the serum TNF-a levels in the patients
with DH when compared to normal subjects (P¼0.0186,
Mann–Whitney Test, one-tailed test).
Patients on a GFD had a mean level of IgA anti-TTG
of 19.2 U/ml compared to a mean value of 109.4 U/ml
in patients on gluten-containing diets (P¼ 0.011, Mann–
Whitney U-test, one-tailed test). Serum IL-8 levels in patients
on GFD were not significantly lower than those of patients on
gluten-containing diets (GFD: mean¼821.5 pg/ml; normal
gluten-containing diet: mean¼797.2 pg/ml). Of interest, the
serum IL-8 levels in three of the four patients on a GFD, that
did not require dapsone or sulfapyridine to control their
skin disease activity, were in the normal range (2.9, 10.2,
10.2, and 650 pg/ml) and all values were lower than the
mean level of DH patients on a normal diet (mean 821 pg/
ml). No significant difference was seen in the mean TNF-a
level between patients on a regular diet and those on a GFD.
Clinical data, treatment status and serum IgA anti-tissue
TTG, cytokines, sE-sel, and sL-selectin values for each subject
are shown in Supplementary Material (Table S1).
DISCUSSION
We have demonstrated that the normal-appearing skin of
patients with DH expresses significantly increased levels of
E-sel mRNA compared to skin from normal subjects, whereas
the expression of ICAM-1 mRNA was not significantly diffe-
rent in DH patients from that seen in anatomically matched
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Figure 4. Serum IL-8 levels are elevated in the sera of patients with DH.
Serum IL-8 is significantly increased in the sera of patients with DH compared
to normal subjects (P¼ 0.024, Mann–Whitney U-test) and to skin disease
controls (P¼ 0.022, Mann–Whitney U-test).
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Figure 5. Serum TNF-a levels are elevated in the sera of patients with DH.
Serum TNF-a is significantly increased in the sera of patients with DH
compared to normal subjects (P¼0.019, Mann–Whitney U-test).
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Figure 3. sE-sel levels are increased in the sera of patients with DH. sE-sel is
significantly elevated in the sera of patients with DH when compared to
normal subjects (P¼0.0250, Mann–Whitney U-test).
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skin from normal subjects. DH patients also showed a
significantly increased level of sE-sel in their sera, suggesting
systemic endothelial cell activation. Despite the lack of
gastrointestinal symptoms or significant active skin disease,
patients with DH also had significantly elevated serum levels
of IL-8, TNF-a, and IgA anti-TTG. These findings support the
hypothesis that the presence of an ongoing gut mucosal
immune response is associated with a systemic immune
response and activation of cutaneous endothelial cells with
expression of E-sel.
In DH, the typical skin lesion is characterized by the
presence of cutaneous IgA deposits and a predominantly
neutrophilic inflammatory infiltrate at the dermal–epidermal
junction. Although perivascular deposits of lymphocytes are
sometimes seen in the lesional skin of patients with DH, little
or no perivascular localization of neutrophils, endothelial
cell destruction, or interstitial dermal infiltrate of neutrophils
or lymphocytes is seen. (Hall, 1992; Fry, 1995; Amerio et al.,
2000; Warren and Cockerell, 2002).
Although the active skin lesions of patients with DH are
well characterized, the mechanisms involved in the devel-
opment of the typical inflammatory infiltrate are not known.
The association of DH with gluten-sensitive enteropathy and
the improvement in the skin lesions of DH while on a GFD
suggest that the ongoing gut inflammation that occurs with
gluten ingestion plays a role in the pathogenesis of DH
(Fry et al., 1973; Reunala et al., 1977).
We have hypothesized that the inflammatory response
to dietary gluten that is present in patients with DH is critical
in partially priming both the neutrophil and the cutaneous
endothelial cell. We have previously demonstrated that
circulating neutrophils from patients with DH show evidence
of partial priming including increased expression of CD11b,
shedding of L-selectin, and increased function of Fc IgA
receptors (Smith et al., 2002). In this report, we set out to
determine if the skin of patients with DH had evidence of
‘‘priming’’ of endothelial cells.
The localization of inflammatory cells in the skin is
initiated by rolling and tethering, a process that is mediated
by E-sel expression on endothelial cells (Lawrence and
Springer, 1993). The extent of the constitutive expression of
E-sel by cutaneous endothelial cells has been controversial.
Some authors report that E-sel is not present in normal skin,
whereas Chong et al. have recently reported that E-sel is
expressed in dermal microvessels of skin removed during
elective surgery (Cotran et al., 1986; Sais et al., 1997; Chong
et al., 2004). We have previously shown that minor trauma
to the skin can increase the expression of E-sel in the
skin (Takeuchi et al., 2003). These results suggest that the
evaluation of E-sel expression in normal skin may be affected
by body location, potentially through the occurrence of prior
minor trauma to the skin. For these reasons, we chose to
study E-sel expression in an area of the skin that is subject to
minimal trauma and rarely develops classical skin lesions of
DH. We have demonstrated that patients with DH have
elevated levels of E-sel mRNA in their inner arm skin that
is significantly greater than that seen in site-matched
skin biopsies from normal subject, suggesting endothelial
activation. Immunohistochemistry also revealed the presence
of E-sel in dermal blood vessels of clinically normal skin of
patients with DH. ICAM-1 mRNA, which is constitutively
expressed in normal skin, was not increased in the skin of
patients with DH when compared to normal subjects.
Increased sE-sel was also present in the serum of
patients with DH. sE-sel has been reported to be increased
in the sera of patients with a wide variety of generalized
inflammatory diseases and conditions including rheumatoid
arthritis, Behc¸ets’ syndrome, inflammatory bowel disease,
and isolated gluten-sensitive enteropathy not associated with
DH (Jelinkova et al., 2000; Kuuliala et al., 2002; Magro et al.,
2004; Sari et al., 2005). Elevation of sE-sel has been thought
to represent endothelial cell activation with subsequent
shedding of E-sel into the serum. In patients with isolated
gluten-sensitive enteropathy, Jelinkova et al. (2000) found an
increased level of sE-sel that was also elevated in patients that
had been on a GFD for 3–15 months. It is of interest that total
control of the skin lesions of patients with DH may require
upto 36 months of a strict GFD, which documents that
significant time is needed to totally control the inflammatory
response in the gut. This clinical observation correlates with
the persistent elevation of sE-sel in the serum after months of
a GFD and is suggestive of persistent cutaneous endothelial
cell activation playing a role in the continued development of
skin lesions in the initial periods of gluten withdrawal from
the diet. Prospective evaluation of sE-sel in patients with DH
both before and during institution of a GFD would be of value
to determine the true relationship between dietary gluten
ingestion, mucosal inflammation and sE-sel levels.
Increased expression of E-sel on endothelial cells has been
associated with exposure to cytokines such as IL-1b and
TNF-a (Bevilacqua and Nelson, 1993; Vestweber and Blanks,
1999). In order to determine if any evidence of a systemic
inflammatory response was present in patients with DH, we
evaluated serum levels of IgA anti-TTG, IL-8, TNF-a, and
soluble L-selectin. The elevated levels of IgA anti-TTG and its
correlation with dietary gluten ingestion is consistent with
ongoing gastrointestinal inflammation in our patients with
DH (Leonard et al., 1985; Dieterich et al., 1999; Kumar et al.,
2001). We have documented additional significant evidence
of systemic inflammation in patients with DH including
elevated levels of serum IL-8 and TNF-a. These elevated
cytokines were found despite the lack of significant skin
disease, but in the presence of ongoing gastrointestinal
mucosal inflammation as demonstrated by the elevated IgA
anti-TTG found in these patients. We were not able to
demonstrate any correlation between the levels of IL-8 or
sE-sel in the serum and the diet status of our patients with
DH. It is important, however, to note that most of our patients
who were on a GFD had not been able to totally discontinue
dapsone therapy. It is well known that it may take as long as
24–36 months of gluten avoidance to discontinue dapsone
therapy, suggesting an ongoing mucosal immune response
(Fry et al., 1973; Garioch et al., 1994). Of interest, three of
four patients who were able to totally control their eruption
with diet had normal serum levels of IL-8, TNF-a, sL-selectin,
sE-sel, and IgA anti-TTG.
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The mechanism that regulates the increased expression
of E-sel in the skin of DH patients is not known. TNF-a is
known to stimulate the expression of endothelial E-sel and
our DH patients had significantly elevated serum levels
of TNF-a, suggesting that TNF-a may play an important role
in the pathogenesis of DH skin lesions. Recently, Liu and
Spolarics (2003) reported that free methemoglobin is a
potent activator of human umbilical vein endothelial cells
in vitro with resultant increased expression of endothelial
cell E-sel. Although this is an intriguing finding given that
patients on dapsone often have elevated methemoglobin
levels, most of the methemoglobin remains within the red
blood cell and is not free methemoglobin. Liu and Spolarics
(2003) estimated that hemolysis of 10% of circulating
red blood cells would be required to produce sufficient
methemoglobin to reach the micromolar levels required
to result in E-sel expression. In our patients on dapsone or
sulfapyridine, eight of nine had normal hemoglobin values,
suggesting minimal hemolysis and therefore minimal free
methemoglobin. A prospective evaluation of sE-sel levels and
free methemoglobin would be of interest to determine if
dapsone may be indirectly leading to endothelial cell
activation in vivo.
In total, these findings suggest that patients with DH have
an ongoing mucosal immune response manifest with elevated
serum levels of IgA-anti-TTG and of proinflammatory
cytokines such as IL-8 and TNF-a. We have previously
demonstrated that patients with DH have circulating neu-
trophils with increased expression of CD11b, decreased cell
surface L-selectin, and increased Fc IgA function, suggesting
partial priming (Smith et al., 2002). In this report, we also
report that the skin of patients with DH shows an increased
expression of dermal endothelial E-sel mRNA, creating a
proinflammatory environment in the skin. Both of these
events would facilitate the development of inflammatory skin
lesions such as are seen in DH. The final step in the
development of a skin lesion, migration across the endothe-
lial barrier into the skin, may require additional local
stimulation with resultant cytokine/chemokine production.
Local cytokine/chemokine production in the presence of the
IgA deposits at the dermal–epidermal junction would allow
for the rolling and tethered neutrophils to firmly adhere and
move to the epidermal–dermal junction with resultant skin
lesions. We have previously demonstrated that minor trauma
to the skin such as rubbing can result in increased expression
of IL-8 and upregulation of E-sel in the skin of normal subjects
(Takeuchi et al., 2003). We hypothesize that the skin lesions
of DH develop when partially primed neutrophils that are
rolling and tethered to activated endothelial cells in DH skin
encounter cytokines/chemokines induced by mild local
trauma, they then firmly adhere and move towards the IgA
present in DH skin. The skin lesions therefore depend on the
ongoing mucosal immune response that ‘‘primes’’ both
neutrophils and endothelial cells and the local trauma that
occurs at the typical locations of elbows and knees. Although
this mechanism remains speculative at the current time, it can
be prospectively examined in patients going on GFDs as well
as through gluten challenge.
These findings also have implications for other cutaneous
manifestations of inflammatory disease of the intestinal tract.
Numerous skin lesions such as pyoderma gangrenosum and
erythema nodosa are associated with inflammatory bowel
disease (Veloso et al., 1996). We would hypothesize that the
ongoing mucosal immune response may prime both effector
inflammatory cells and the skin, and with relatively minor
local trauma result in the development of skin lesions such as
occur in skin diseases such as pyoderma gangrenosum.
Further prospective study of patients with inflammatory
bowel disease and associated skin lesions are needed to
directly address this hypothesis.
In summary, we have demonstrated that patients with DH
have evidence of an ongoing low-grade systemic inflamma-
tory response with elevated serum IL-8 and TNF-a, which
is associated with evidence of cutaneous endothelial cell
activation with increased expression of E-sel mRNA and
protein in the skin and sE-sel in the serum. These findings
coupled with previous characterization of partial priming of
circulating neutrophils in patients with DH suggest that the
ongoing low-grade mucosal response represents a proinflam-
matory event resulting in partial ‘‘priming’’ of both the target
organ (skin) as well as the effector cell (neutrophils), that
when local trauma occurs leads to the development of skin
lesions of DH. Further investigation of the systemic response
to dietary gluten challenge will allow for this hypothesis to
be directly addressed. In addition, these findings suggest
a pathogenetic mechanism that may play a role in many
cutaneous manifestations of gastrointestinal inflammation.
MATERIALS AND METHODS
Subjects
Sera were obtained from 50 patients with DH (36 male, 14 female;
mean age: 50.8 years, age range¼ 11–94 years). Fifteen patients
reported adhering to a GFD (duration of diet: 3 months–15 years),
three patients a reduced gluten diet, and 32 patients a normal diet.
Four patients on a GFD were taking no medication for their DH, nine
were taking dapsone (mean dosage: 54.2 mg/day) and two patients
were taking sulfapyridine (500 mg/day). Twenty-five patients on
reduced gluten or normal diets were taking dapsone alone (mean
dosage: 114 mg/day), four patients sulfapyridine alone (mean
dosage: 1,054 mg/day), two dapsone and sulfapyridine (mean
dosage: dapsone 100 mg/day; sulfapyridine 1,500 mg/day), and four
patients were on no medication. All patients with DH were
diagnosed by the presence of typical clinical and histologic features
and the presence of granular IgA deposits at the dermal–epidermal
junction by direct immunofluoresence of normal-appearing skin.
Sera were also obtained from 10 patients with other immune-
mediated skin diseases (five pemphigus vulgaris, two linear IgA
dermatosis, one cicatricial pemphigoid, two bullous pemphigoid)
(five male, five female, mean age 47.7 years) and 10 normal subjects
(five male, five female, mean age 38.1 years) with no evidence of
gastrointestinal or skin disease.
Skin biopsies (4 mm) were obtained from the upper inner arm of
11 patients with DH at a time when the patients had no active skin
lesions. Five of the patients were on dapsone alone (four patients
100 mg/day; one patient 200 mg/day), three on sulfapyridine alone
(two at 500 mg/day; one at 1,000 mg/day), one on GFD (2 weeks on
www.jidonline.org 1335
RP Hall et al.
Cutaneous Endothelial Cell Activation in Normal Skin
diet) and dapsone (100 mg/day), and two on GFD alone (44 years).
Normal subject skin biopsies were obtained from the inner arm of
12 individuals with no clinical evidence or history of skin or
gastrointestinal disease. Skin biopsies were immediately placed into
a guanidium isothiocyanate, lysing buffer (RNeasy mini kits; Qiagen,
Valencia, CA), homogenized using Omni-TH tissue homogenizer
(Omni International, Warrenton, VA) and stored at 801C until total
RNA was extracted as described below. Skin biopsies were analyzed
for the presence of E-sel and ICAM-1 mRNA. Skin biopsies were also
analyzed by immunohistochemistry for the presence of E-sel and
ICAM-1.
The Duke University Health System Institutional Review Board
approved all studies and consent was obtained from all subjects. This
study was performed according to The Declaration of Helsinki
Principles.
Real-time quantitative reverse transcriptase-PCR
Total RNA was extracted from skin biopsies from patients, normal
subjects and from human umbilical vein endothelial cells and cDNA
prepared as described previously (Takeuchi et al., 2003). Measure-
ment of gene expression was performed utilizing the ABI prism 7700
Sequence Detection System (Applied Biosystems, Foster City, CA) as
described previously (Livak et al., 1995; Heid et al., 1996). ICAM-1
and E-sel primer and probes were utilized as described previously
(Takeuchi et al., 2003).
For analysis of E-sel mRNA and ICAM-1 expression, a standard
curve was constructed with serial dilutions of cDNA obtained from
single sample of human umbilical vein endothelial cells that had
been stimulated for 4 hours by TNF-a. Relative quantitation of E-sel
and ICAM-1 expression was determined using the relative standard
curve method as described previously (User Bulletin no. 2; Applied
Biosystems, Foster City, CA) (Takeuchi et al., 2003). Individual
results were normalized utilizing 18S ribosomal RNA as an internal
control with TaqMan rRNA control reagents (Applied Biosystems,
Foster City, CA). The gene expression, normalized to 18S ribosomal
RNA expression, from the inner arm skin biopsy of a single normal
subject was designated as the normal value and the ratio of each
individual sample to this level of E-sel or ICAM-1 expression was
calculated and expressed as an n-fold difference (subject mRNA
expression/normal subject expression). All PCR assays of E-sel and
ICAM-1 were performed in triplicates.
Immunohistochemistry
Normal, inner arm skin from six patients with DH was studied for
E-sel and ICAM-1 expression as described previously (Takeuchi
et al., 2003). Primary murine anti-human monoclonal antibodies
(5mg/ml) directed against E-sel (CD62E) and ICAM-1 (CD54) (R&D
Systems Inc., Minneapolis, MN) were utilized with an isotype-
matched antibody (5 mg/ml) negative control (MOPC21 (IgG1); Sigma
Immuno Chemicals, St Louis, MO).
Serum IL-8, TNF-a, sE-sel, soluble L-selectin levels, and IgA
anti-TTG antibody levels
Serum levels of IL-8, TNF-a, sE-sel, and soluble L-selectin were
analyzed using commercially available ELISA kits (R&D Systems,
Minneapolis, MN). Serum IgA anti-TTG antibody levels were
determined using commercially available ELISA kits (Orgentec
Diagnostika, Mainz, Germany).
Statistics
Samples were analyzed using the non-parametric, Mann–Whitney
U-test to test for a difference between the medians of two
independent samples using Analyse-it for Microsoft Excel (Analyse-
It Software Ltd, Leeds, UK). Statistical significance was assumed for a
P-value of less than or equal to 0.05. Correlation between different
serum markers was analyzed using Spearman’s correlation (Analyse-
It Software Ltd, Leeds, UK).
SUPPLEMENTARY MATERIAL
Table S1. Clinical and laboratory patient data.
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